Showing results (51-60 of 168) with videos related to
Sort By:
Pageof 17
British Journal of Haematology|June 28, 2024
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana LinfomiFederica Cavallo, Michele Clerico, Elisa Lucchini, et al.Annals of Hematology|April 17, 2024
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life surveyAndrea Duminuco, Alessandra Romano, Isacco Ferrarini, et al.Hematological Oncology|April 30, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paperSarah Bailly, Guillaume Cartron, Sridhar Chaganti, et al.Journal for Immunotherapy of Cancer|July 17, 2021
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cellsAnna Dalla Pietà, Elisa Cappuzzello, Pierangela Palmerini, et al.British Journal of Haematology|December 8, 2011
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio LinfomiFrancesco Merli, Stefano Luminari, Fiorella Ilariucci, et al.Cancer|July 7, 2011
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseAlessandra Tedeschi, Giulia Benevolo, Marzia Varettoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneTina Marie Green, Ken H Young, Carlo Visco, et al.Cancers|December 10, 2021
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell LymphomaGiulia Bega, Jacopo Olivieri, Marcello Riva, et al.Haematologica|April 11, 2020
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphomaJulia Garcia-Reyero, Nerea Martinez Magunacelaya, Sonia Gonzalez de Villambrosia, et al.Bioorganic & Medicinal Chemistry|July 2, 2014
Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitorsElena Casale, Nadia Amboldi, Maria Gabriella Brasca, et al.Pageof 17